| abstract |
The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the "Expresion and Nuclear Retention Element" (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV). |